Literature DB >> 15172640

Molecular cloning, isolation and characterisation of ERK3 gene from chewing-tobacco induced oral squamous cell carcinoma.

Rekha Rai1, Alka Mahale, Dhananjaya Saranath.   

Abstract

The mitogen activated serine/threonine kinases (MAPKs) constitute extracellular signal-regulated protein kinases (ERKs), c-Jun N-terminal kinases (JNKs) and p38 MAPK, with an important role in cell proliferation and transformation. Earlier studies from our laboratory had indicated a role for MAPK pathway in oral cancer. Our current study was aimed at examining the role of a MAPK-ERK3, in chewing-tobacco associated oral squamous cell carcinoma. We constructed a cDNA library from primary oral cancer tissue, cloned and isolated the ERK3 gene. The gene was sequenced and the sequence submitted to GenBank (Accession number AF420474). The oral cancer ERK3 clone demonstrated 100% homology to human ERK3 isolated from fetal skeletal muscle, with four specific nucleotide alterations in the non-coding region of the gene, comprising deletion of 'TTT' between 2701 and 2705 nt; 'G' to 'T' substitution at 188 nt; insertion of 'A' between 121 and 122 nt, and insertion of 'CTTTA' between 3391 and 3392 nt. Southern analysis of EcoRI genomic digests indicated ERK3 specific fragments of 11, 8.6, 6.5 and 3.2 kb sizes. The mRNA transcript analysis defined a single transcript of 4.5 kb. RT-PCR analysis revealed a three- to eight-fold increase in ERK3 expression in a majority (90%) of oral cancer tissues and peripheral blood cells (61.5%) of the patients, whereas absence or low levels of expression was observed in peripheral blood cells of 74% clinically normal healthy individuals with no tobacco habits, and overexpression in PBC from 26% normal individuals. The alterations in the non-coding region of ERK3 gene cloned from oral cancer tissue, may affect stability or regulation of mRNA, resulting in overexpression in the patient samples. The overexpression of the gene in the normal healthy individuals may be indicative of increased risk of developing oral cancers in this group.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15172640     DOI: 10.1016/j.oraloncology.2004.01.010

Source DB:  PubMed          Journal:  Oral Oncol        ISSN: 1368-8375            Impact factor:   5.337


  6 in total

1.  Activation loop phosphorylation of ERK3 is important for its kinase activity and ability to promote lung cancer cell invasiveness.

Authors:  Lobna Elkhadragy; Hadel Alsaran; Marion Morel; Weiwen Long
Journal:  J Biol Chem       Date:  2018-08-30       Impact factor: 5.157

2.  The atypical mitogen-activated protein kinase ERK3 is essential for establishment of epithelial architecture.

Authors:  Chika Takahashi; Koichi Miyatake; Morioh Kusakabe; Eisuke Nishida
Journal:  J Biol Chem       Date:  2018-04-19       Impact factor: 5.157

3.  Tumour promoting and suppressing roles of the atypical MAP kinase signalling pathway ERK3/4-MK5.

Authors:  Sergiy Kostenko; Gianina Dumitriu; Ugo Moens
Journal:  J Mol Signal       Date:  2012-07-16

4.  A regulatory BMI1/let-7i/ERK3 pathway controls the motility of head and neck cancer cells.

Authors:  Lobna Elkhadragy; Minyi Chen; Kennon Miller; Muh-Hwa Yang; Weiwen Long
Journal:  Mol Oncol       Date:  2017-01-12       Impact factor: 6.603

5.  ERK3 is transcriptionally upregulated by ∆Np63α and mediates the role of ∆Np63α in suppressing cell migration in non-melanoma skin cancers.

Authors:  Eid S Alshammari; Amjad A Aljagthmi; Andrew J Stacy; Mike Bottomley; H Nicholas Shamma; Madhavi P Kadakia; Weiwen Long
Journal:  BMC Cancer       Date:  2021-02-12       Impact factor: 4.430

6.  L290P/V mutations increase ERK3's cytoplasmic localization and migration/invasion-promoting capability in cancer cells.

Authors:  Hadel Alsaran; Lobna Elkhadragy; Astha Shakya; Weiwen Long
Journal:  Sci Rep       Date:  2017-11-03       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.